CCCC vs KEY · rev $35.6M vs P/E 13, rev $7.51B
C4 Therapeutics Inc (CCCC) versus KeyCorp (KEY) — a side-by-side from cached financials, not a winner call.
C4 Therapeutics Inc (CCCC) is a biotechnology company listed on US.
KeyCorp (KEY) is a banks - regional company listed on US.
Latest reported CCCC revenue for 2024-12-31 was $35.6M. Net income was -$105.3M. Revenue was up 71.4% from 2023-12-31 to 2024-12-31. CCCC currently screens at market cap $425.7M.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
CCCC currently screens at market cap $425.7M. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Not investment advice. Open the CCCC and KEY stock pages for the full models.
Not investment advice.